Drug profile · INN
bupropion hydrobromide
APLENZIN
bupropion hydrobromide (APLENZIN) is a dopamine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — bupropion hydrobromide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 13
- Data quality
- 0.84
Quick answer
bupropion hydrobromide (APLENZIN) is a dopamine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine transporter inhibitor
Primary target: Sodium-dependent dopamine transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is bupropion hydrobromide?
bupropion hydrobromide (APLENZIN) is a dopamine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for bupropion hydrobromide?
APLENZIN is a marketed brand name for bupropion hydrobromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bupropion hydrobromide?
bupropion hydrobromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.